Corvus Pharmaceuticals

Price & Volume

Stats

52W Range	$2.54-$9.55
Market Cap	$665.4M
Shares Short	9M

Financials

Revenue (12 Mos)	$0
Revenue Growth (YoY)	0%
Gross Profit (12 Mos)	$0
Diluted EPS	-$0.54

News

Yahoo Finance • 14 days ago

Corvus outlines January data readout for soquelitinib extension study as Phase II atopic dermatitis trial set for Q1 2026

Yahoo Finance • 16 days ago

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

Yahoo Finance • 22 days ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Yahoo Finance • last month

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

About

CEO	Dr. Richard A. Miller M.D.
Address	901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	31